RxDoctor Payments Data

Vijaya Mummadi, MD

Internal Medicine · Dallas, TXNPI 1003026410

Payments from drug & device makers

$3,112in general payments, 2019–2025

Across 183 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$451
  • Novo Nordisk$403
  • AstraZeneca$396
  • Amarin Pharma, Inc.$278
  • Lilly USA, LLC$267
  • Pfizer$263
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$3,09499%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,112 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$202,503
Medicare patients
167
Services billed
4,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$32,127
MounjaroTirzepatide15$25,002
Valsartan32$662
Rosuvastatin Calcium56$660
Gabapentin45$605
Duloxetine Hcl18$471
Albuterol Sulfate HfaAlbuterol Sulfate16$457
Fluticasone Propionate11$438
Atorvastatin Calcium58$437
Fenofibrate11$404
Levothyroxine Sodium25$298
Lisinopril28$257
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide17$190
Metformin Hcl12$174
Hydralazine Hcl24$172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$403$32,12722 claims
Lilly USA, LLCMounjaro$267$25,00215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →